ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1463	National Cancer Institute	Html	en	Renal Cell Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of renal cell cancer.	2-week washout period 0.566416 Transitional Cell Cancer 0.481465 treatment 0.601534 Patient Preference Study 0.474292 sunitinib treatment 0.529856 10-week treatment period 0.482517 VEGF receptors 0.467264 well-differentiated renal adenocarcinomas 0.509726 pazopanib arm 0.470964 sunitinib side effects 0.517044 true treatment break 0.474342 primary endpoint 0.499973 patients preferred pazopanib 0.531227 immediately surrounding tissue 0.462945 6-week treatment cycle 0.515867 trial 0.472067 Late tumor recurrence 0.47026 Pazopanib Versus Sunitinib 0.55357 cytoreductive nephrectomy extends 0.466923 High-dose IL-2 0.463042 patient treatment 0.463771 occasional selected patients 0.50375 overall survival 0.481487 rating scale 0.463587	toxic effects 0.499682 axitinib versus sorafenib 0.467683 sorafenib patients 0.470445 sunitinib 0.625595 renal cell cancer 0.570239 recurrent renal cell 0.504482 metastatic disease 0.476849 external-beam radiation therapy 0.463579 patients 0.74513 Metastatic Kidney Cancer 0.465785 initial cytoreductive nephrectomy 0.466065 median PFS time 0.4636 renal adenomas 0.481736 4-week treatment cycle 0.477666 renal cell carcinoma 0.969838 renal cell carcinoma. 0.553709 transitional cell carcinomas 0.485832 clear-cell renal cell 0.607225 renal cell cancers 0.532142 renal pelvis 0.520062 10-week treatment periods 0.476333 metastatic renal cell 0.598995 renal cell carcinomas 0.527788	CLICK HERE
1524	National Cancer Institute	Html	en	Endometrial Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of endometrial cancer.	cancer treatment 0.541916 Lymph node dissection 0.478324 metastatic endometrial cancer 0.510561 body 0.511838 PDQ cancer information 0.531329 clinical trial search 0.465384 uterus 0.585793 endometrial cancer spreads 0.509404 mTOR inhibitors 0.464666 clinical trials 0.736061 cancer information summary 0.508345 clinical trial 0.5843 Low-risk endometrial cancer 0.501844 breast cancer patients 0.483969 patients 0.494506 NCI PDQ cancer 0.479485 malignant tumor cells 0.467809 lymph nodes 0.52827 endometrial hyperplasia 0.468477 radiation therapy 0.605187 Treatment Editorial Board 0.469208 endometrial cancer 0.889926 radical hysterectomy 0.471844 treatment 0.622425 cancer prevention 0.463817	new cancer treatments 0.470535 NCI-supported cancer 0.463476 cancer cells 0.753566 Cancer Information Service 0.471559 specific cancer cells 0.479989 treatment clinical trials 0.48357 High-risk endometrial cancer 0.500552 endometrial tissue 0.464689 National Cancer Institute 0.508844 new treatment 0.504217 cervix 0.474629 external radiation therapy 0.482834 non-polyposis colon cancer 0.477796 tissue samples 0.463584 cancer research process 0.465542 cancer clinical trials 0.501833 stage 0.522219 Endometrial Cancer Treatment 0.516218 Recurrent endometrial cancer 0.629078 fallopian tubes 0.494755 cancer information summaries 0.469865 treatment options 0.466033 comprehensive cancer information 0.469896 internal radiation therapy 0.504839	CLICK HERE
1577	National Cancer Institute	Html	en	Retinoblastoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of retinoblastoma in children.	cancer treatment 0.489298 body 0.467706 type 0.422666 PDQ cancer information 0.456409 clinical trial search 0.418893 retinoblastoma 0.865388 retinoblastoma treatment centers 0.451209 systemic chemotherapy 0.574478 regular eye exams 0.443823 clinical trials 0.855386 recurrent intraocular retinoblastoma 0.415908 high-dose chemotherapy 0.465125 cancer information summary 0.42823 clinical trial 0.564195 patients 0.408556 eye 0.840016 radiation therapy 0.862799 optic nerve 0.459799 child 0.430789 heritable form 0.409154 treatment 0.773723 bilateral intraocular retinoblastoma 0.418197 heritable retinoblastoma 0.466245 Nonheritable retinoblastoma 0.41969 cancer cells 0.573196	extraocular retinoblastoma 0.479879 retinoblastoma cells 0.416299 Intravitreal chemotherapy 0.407999 treatment clinical trials 0.426091 RB1 gene 0.435629 National Cancer Institute 0.44282 spinal cord 0.437008 intraocular retinoblastoma 0.468181 effects cancer treatment 0.415229 new treatment 0.441768 artery infusion chemotherapy 0.538311 external-beam radiation therapy 0.642309 recurrent extraocular retinoblastoma 0.414269 ophthalmic artery infusion 0.504849 metastatic retinoblastoma 0.407008 trilateral retinoblastoma 0.466869 bone marrow 0.434989 cancer clinical trials 0.449674 cavitary retinoblastoma 0.436997 stem cell rescue 0.535096 tumor 0.495126 retinoblastoma spreads 0.40533 internal radiation therapy 0.438773 cancer 0.972687	CLICK HERE
1581	National Cancer Institute	Html	en	Thyroid Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of thyroid cancer.	thyroid hormone 0.462109 thyroid cells 0.459144 thyroid hormone levels 0.441028 body 0.475956 thyroid nodules 0.440882 thyroid hormone replacement 0.418097 type 0.402327 PDQ cancer information 0.417269 clinical trial search 0.44196 clinical trials 0.712208 thyroid cancer spreads 0.460066 radioactive iodine therapy 0.447344 cancer information summary 0.398763 clinical trial 0.54371 thyroid disease 0.440863 patients 0.405549 fine-needle aspiration biopsy 0.401121 sentinel lymph node 0.409752 thyroid tumor 0.430395 lymph nodes 0.45279 thyroid cancer cells 0.479847 thyroid cancer treatment 0.491155 radiation therapy 0.478836 medullary thyroid cancer 0.563411 tyrosine kinase inhibitor 0.42467	thyroid scan 0.39797 treatment 0.554504 childhood thyroid cancer 0.480138 thyroid nodule 0.461177 follicular thyroid cells 0.442093 metastatic thyroid cancer 0.461409 healthy thyroid 0.426685 undifferentiated thyroid cancer 0.481926 thyroid cancer 0.866042 cancer cells 0.55043 thyroid tissue 0.43819 familial medullary thyroid 0.436692 anaplastic thyroid cancer 0.503212 National Cancer Institute 0.411413 Thyroid hormones 0.426342 external radiation therapy 0.459156 papillary thyroid cancers 0.4232 differentiated thyroid cancer 0.481235 thyroid uses iodine 0.446079 cancer clinical trials 0.453504 stage 0.433394 tumor 0.440267 cancer 0.979846 information 0.45122	CLICK HERE
1704	National Cancer Institute	Html	en	Psychological Stress and Cancer	A fact sheet that describes the effects of stress on the body, the results of research on the relationship between stress and cancer, and information about coping with stress.	Sood AK 0.622496 cancer treatment 0.603243 primary breast cancer 0.597411 Antoni MH 0.570507 human cancer cells 0.605494 family member 0.588007 psychological distress 0.593032 fact sheet 0.615559 mammary fat pads 0.570769 emotional pressure 0.583244 Health care providers 0.574848 risky behaviors 0.581446 cancer metastasis 0.572171 social support 0.574381 triple-negative breast cancer 0.658004 various psychological factors 0.615469 Lutgendorf SK 0.681275 cancer patients 0.656706 cancer survival 0.572148 stress cause cancer 0.708673 blood sugar levels 0.578812 Clinical Oncology 0.599718 speed heart rate 0.575901 ovarian carcinoma patients 0.577415	higher rates 0.57609 specific psychological conditions 0.622117 Psychological Bulletin 0.579687 elevated tumor norepinephrine 0.576809 psychological stress 0.974362 beta blockers 0.5732 normal life activities 0.583211 physical health problems 0.585785 drinking alcohol 0.576593 cancer outcomes 0.570999 biobehavioral signaling pathways 0.570101 stress management techniques 0.670628 clinical health psychologist 0.575253 Cancer Research 0.5705 stress hormone norepinephrine 0.675379 poorer clinical outcomes 0.584728 stress hormones 0.675405 people 0.602029 certain stress hormones 0.663467 New patient-centered care 0.571423 close family member 0.58133 Related Resources 0.579385 et al 0.674807 Related Resources section 0.573303	CLICK HERE
1740	National Cancer Institute	Html	en	Hair Dyes and Cancer Risk	A fact sheet that reviews research about the possibility of a connection between personal hair dye use and cancer.	female breast cancer 0.364162 hair dye 0.94208 hair dye products 0.547022 hair dyes 0.824788 Kupelnick B. Personal 0.356107 Modern hair dyes 0.445893 C. Personal hair 0.381701 case-control study 0.408793 bladder cancer 0.729938 consumer exposure study 0.34979 permanent hair dye 0.484417 increased risk 0.395633 case-control studies 0.347772 bladder cancer risk 0.47239 Montes-Martinez A. Personal 0.354703 IARC Working Group 0.350056 permanent hair dyes 0.502056 MR. Bladder cancer 0.389163 American Journal 0.365295 temporary hair dyes 0.442658 hair coloring products 0.388447 currently marketed products 0.354822 leukemia/small lymphocytic lymphoma 0.349931 colorless dye 0.417079 A. Bladder cancer 0.391043	Cancer Epidemiology Biomarkers 0.364493 International Journal 0.379963 public health impact 0.349406 black permanent dyes 0.401612 color dyes 0.375257 Personal permanent hair 0.383955 United States 0.383182 adult acute leukemia 0.391088 non-Hodgkin lymphoma 0.350907 conflicting results 0.412706 bladder cancer study 0.39321 earlier hair dyes 0.42871 personal hair dye 0.756765 studies 0.389653 bladder-cancer risk 0.359564 public health 0.351318 dark-colored dyes 0.399225 follicular lymphoma 0.348182 recent dye formulations 0.42394 aromatic amines 0.360034 hair dye formulations 0.474224 specific NHL subtypes 0.351636 hair dye users 0.497516 et al 0.482744	CLICK HERE
1833	National Cancer Institute	Html	es	Tratamiento de los tumores carcinoides gastrointestinales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores carcinoides gastrointestinales.	metastatic carcinoid tumor 0.417651 carcinoides gi 0.793345 enfermedad cardíaca carcinoide 0.432281 carcinoides duodenales 0.478754 células ec 0.425941 tracto gi 0.460962 Sin embargo 0.46213 tumores carcinoides gi 0.491452 PDQ Tumores neuroendocrinos 0.416768 imaging features with 0.416291 células neuroendocrinas gi 0.414118 marcadores carcinoides 0.432817 Exp Clin Cancer 0.413418 Cancer Res 0.421273 Res Clin Endocrinol 0.414031 Clin Gastroenterol 0.414029 síntomas carcinoides 0.431545 Pract Res Clin 0.438075 síndrome carcinoideo 0.506176 Clin Cancer Res 0.414666 patients with 0.502884 carcinoid tumors 0.605663 Best Pract Res 0.431995 Clin Endocrinol Metab 0.422923 carcinoid heart 0.423722	carcinoides celulares cse 0.43559 carcinoide celular cse 0.415154 tumores carcinoides 0.966863 neuroendocrine tumors 0.59007 TNE pancreáticos 0.414445 gastrointestinal tract 0.419836 tumores carcinoides gastrointestinales 0.615452 Surg Pathol 0.422847 Dig Dis Sci 0.415197 tumores tipo 0.415164 multiple endocrine neoplasia 0.418143 CSE tipo 0.414261 TNE GI 0.460772 tumores neuroendocrinos 0.4479 carcinoides esporádicos gi 0.445952 Surg Oncol 0.418143 with von recklinghausen 0.424868 somatostatin receptor 0.413855 neuroendocrine tumour 0.454787 tumores neuroendocrinos pancreáticos 0.419002 carcinoid tumor with 0.413498 Acad Sci 0.415384 gastrointestinal carcinoids 0.415688 tumores duodenales 0.41576	CLICK HERE
1876	National Cancer Institute	Html	es	Tratamiento de los tumores de ovario de bajo potencial maligno (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores de ovario de bajo potencial maligno.	estadio lV 0.336073 Obstet Gynecol 0.332535 Are borderline tumors 0.338893 Radium Hospital from 0.383601 low malignant 0.947577 Norwegian Radium Hospital 0.384329 Abeler VM 0.345874 long-term follow-up 0.429878 serous tumors 0.367951 Leake JF 0.387334 ovary treated 0.34981 Instituto Nacional 0.327748 malignant potential with 0.326796 Rosenshein NB 0.34897 Federation Internationale 0.32197 University Medical Center 0.328522 Kaern J 0.406737 endometrioid tumors 0.337973 Gynecologic Oncology Group 0.336842 Gynecol Oncol 0.811816 lavados peritoneales 0.350751 New York University 0.326742 Icb Tumor 0.324006 retrospective study 0.363127 cellular dna content 0.335807	Bell DA 0.339598 patients with borderline 0.366646 malignant potential treated 0.323909 borderline tumors with 0.347412 borderline tumors 0.629125 clinicopathologic features 0.350407 tumores aneuploides 0.321014 estadio ia 0.33807 Oncology Group study 0.347633 with borderline tumors 0.383311 IIIa Tumor 0.323737 Kurman RJ 0.323851 PDQ Tratamiento 0.323544 Gynecol Pathol 0.337197 New York 0.330732 York University Medical 0.327419 Currie JL 0.350075 Ovarian epithelial tumors 0.334479 Clin Oncol 0.355682 Tropé CG 0.345953 Lage JM 0.321478 tumor residual macroscópico 0.331365 Gynecol Cancer 0.321099 serous borderline tumors 0.4289	CLICK HERE
1945	National Cancer Institute	Html	es	Efectos tardíos del tratamiento anticanceroso en la niñez (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de los problemas de salud que aparecen una vez que termina el tratamiento del cáncer.	cancer statistics 0.312893 among adult survivors 0.309342 health insurance 0.30576 childhood leukemia survivors 0.314627 Marrow Transplant Survivor 0.306695 largo plazo 0.353459 Cancer Survivor cohort 0.310798 CA Cancer 0.308516 group long-term follow-up 0.307764 mortality among 5-year 0.309974 health conditions 0.3067 young adult cancers 0.387348 late mortality 0.309117 Ness KK 0.312945 among childhood cancer 0.329959 adult survivors 0.341543 Hudson MM 0.322937 among survivors 0.313213 British Childhood Cancer 0.315849 utilization among long-term 0.306183 childhood cancer 0.973475 cancer survivor study 0.608871 late effects 0.312383 SEER Cancer Statistics 0.308306 long-term survivors 0.338777	health care utilization 0.307102 Survivor Study cohort 0.310239 chronic health conditions 0.305835 among adolescent survivors 0.308292 Care Cancer 0.309376 among 5-year survivors 0.328567 Pediatr Blood Cancer 0.42011 oncology group long-term 0.310223 adolescent cancers 0.313982 efectos tardíos 0.375703 survivors research program 0.306998 report from 0.396085 National Cancer Institute 0.308232 Oeffinger KC 0.306859 health care 0.314251 mortality among survivors 0.308816 Clin Oncol 0.375569 childhood cancer survivor 0.872407 medical care 0.307228 among long-term survivors 0.315379 late mortality among 0.306982 long-term follow-up guidelines 0.320022 Outcomes Among Childhood 0.309917 children's oncology group 0.433388	CLICK HERE
3678	National Cancer Institute	Html	en	NCI Outstanding Investigator Award Recipients	Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.	Professor 0.818386 cancer cell fate 0.872486 tumor interstitial fluid 0.811256 Institution 0.848074 brain cancer stem 0.81847 Salk Institute Cancer 0.836669 cancer therapy 0.800257 ccRCC tumor metabolism 0.813028 cancer stem cell 0.87789 Harvard Medical School 0.902146 Institute Cancer Center 0.918217 Mount Sinai Cancer 0.82427 interactive research areas 0.831532 new therapeutic targets 0.831101 Tisch Cancer Institute 0.836924 tumor suppressor functions 0.808451 Cell Biology Laboratory 0.802354 clinical cancer research 0.915827 Hopkins University School 0.800509 Medical Research 0.805386 molecular mechanisms 0.847735 human cancer metabolism 0.844789 kidney cancer subtype 0.813888 Cancer Research Program 0.87416 mouse models 0.817082	leukemia cell metabolism 0.821118 Cancer Research Center 0.897578 cancer cell metabolism 0.867114 cancer cells 0.87218 Stem Cell Biology 0.799482 distinct cell types 0.801724 Anderson Cancer Center 0.828569 cancer research 0.977431 Adolphus Pfeiffer Professor 0.801659 HGG cancer cell 0.848375 tumor suppressor gene 0.80279 Center Research Institute 0.861555 Title 0.835958 Cancer Society Research 0.870208 Stem Cell Research 0.847258 Cell Biology 0.815108 tumor microenvironment signals 0.812505 Cancer Imaging Research 0.895426 Cell Biology Department 0.805035 acute lymphoblastic leukemia 0.839865 Bakar Distinguished Professor 0.809836 Wistar Institute Cancer 0.864712 M. Temin Professor 0.801808 tumor microenvironment 0.889603	CLICK HERE